Oncobiologics (OTLK) Competitors

Oncobiologics logo
$0.36 -0.04 (-8.94%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$0.37 +0.01 (+1.77%)
As of 08:14 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

OTLK vs. TECX, MPLT, IRD, RZLT, and SVA

Should you buy Oncobiologics stock or one of its competitors? Oncobiologics's main competitors and comparable companies include Tectonic Therapeutic (TECX), Maplight Therapeutics (MPLT), Opus Genetics (IRD), Rezolute (RZLT), and Sinovac Biotech (SVA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Oncobiologics compare to Tectonic Therapeutic?

Oncobiologics (NASDAQ:OTLK) and Tectonic Therapeutic (NASDAQ:TECX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.

In the previous week, Oncobiologics and Oncobiologics both had 1 articles in the media. Tectonic Therapeutic's average media sentiment score of 1.40 beat Oncobiologics' score of 0.91 indicating that Tectonic Therapeutic is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Oncobiologics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Tectonic Therapeutic
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Oncobiologics has higher revenue and earnings than Tectonic Therapeutic. Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oncobiologics$1.35M65.03-$62.42M-$0.77N/A
Tectonic TherapeuticN/AN/A-$74.15M-$4.63N/A

Oncobiologics' return on equity of 0.00% beat Tectonic Therapeutic's return on equity.

Company Net Margins Return on Equity Return on Assets
OncobiologicsN/A N/A -254.82%
Tectonic Therapeutic N/A -37.69%-35.65%

Oncobiologics currently has a consensus target price of $5.20, indicating a potential upside of 1,342.04%. Tectonic Therapeutic has a consensus target price of $69.17, indicating a potential upside of 244.46%. Given Oncobiologics' higher probable upside, research analysts clearly believe Oncobiologics is more favorable than Tectonic Therapeutic.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oncobiologics
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.20
Tectonic Therapeutic
1 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
2 Strong Buy rating(s)
2.80

Oncobiologics has a beta of 0.75, indicating that its share price is 25% less volatile than the broader market. Comparatively, Tectonic Therapeutic has a beta of 3.51, indicating that its share price is 251% more volatile than the broader market.

11.2% of Oncobiologics shares are owned by institutional investors. Comparatively, 62.6% of Tectonic Therapeutic shares are owned by institutional investors. 1.8% of Oncobiologics shares are owned by company insiders. Comparatively, 39.8% of Tectonic Therapeutic shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Tectonic Therapeutic beats Oncobiologics on 8 of the 13 factors compared between the two stocks.

How does Oncobiologics compare to Maplight Therapeutics?

Oncobiologics (NASDAQ:OTLK) and Maplight Therapeutics (NASDAQ:MPLT) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, media sentiment, analyst recommendations, dividends, earnings and institutional ownership.

Oncobiologics has higher revenue and earnings than Maplight Therapeutics. Oncobiologics is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oncobiologics$1.35M65.03-$62.42M-$0.77N/A
Maplight TherapeuticsN/AN/A-$161.15M-$42.31N/A

Oncobiologics presently has a consensus price target of $5.20, indicating a potential upside of 1,342.04%. Maplight Therapeutics has a consensus price target of $29.50, indicating a potential upside of 349.01%. Given Oncobiologics' higher possible upside, research analysts clearly believe Oncobiologics is more favorable than Maplight Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oncobiologics
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.20
Maplight Therapeutics
1 Sell rating(s)
4 Hold rating(s)
9 Buy rating(s)
4 Strong Buy rating(s)
2.89

In the previous week, Maplight Therapeutics had 4 more articles in the media than Oncobiologics. MarketBeat recorded 5 mentions for Maplight Therapeutics and 1 mentions for Oncobiologics. Oncobiologics' average media sentiment score of 0.91 beat Maplight Therapeutics' score of 0.90 indicating that Oncobiologics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Oncobiologics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Maplight Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Oncobiologics' return on equity of 0.00% beat Maplight Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
OncobiologicsN/A N/A -254.82%
Maplight Therapeutics N/A -62.67%-59.69%

11.2% of Oncobiologics shares are held by institutional investors. 1.8% of Oncobiologics shares are held by insiders. Comparatively, 3.8% of Maplight Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Oncobiologics beats Maplight Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Oncobiologics compare to Opus Genetics?

Oncobiologics (NASDAQ:OTLK) and Opus Genetics (NASDAQ:IRD) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.

In the previous week, Opus Genetics had 17 more articles in the media than Oncobiologics. MarketBeat recorded 18 mentions for Opus Genetics and 1 mentions for Oncobiologics. Oncobiologics' average media sentiment score of 0.91 beat Opus Genetics' score of 0.21 indicating that Oncobiologics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Oncobiologics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Opus Genetics
4 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Oncobiologics has a beta of 0.75, suggesting that its stock price is 25% less volatile than the broader market. Comparatively, Opus Genetics has a beta of 0.8, suggesting that its stock price is 20% less volatile than the broader market.

Oncobiologics has a net margin of 0.00% compared to Opus Genetics' net margin of -1,726.70%.

Company Net Margins Return on Equity Return on Assets
OncobiologicsN/A N/A -254.82%
Opus Genetics -1,726.70%N/A -134.07%

Oncobiologics currently has a consensus target price of $5.20, indicating a potential upside of 1,342.04%. Opus Genetics has a consensus target price of $13.29, indicating a potential upside of 228.04%. Given Oncobiologics' higher probable upside, analysts plainly believe Oncobiologics is more favorable than Opus Genetics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oncobiologics
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.20
Opus Genetics
1 Sell rating(s)
1 Hold rating(s)
16 Buy rating(s)
1 Strong Buy rating(s)
2.89

11.2% of Oncobiologics shares are held by institutional investors. Comparatively, 15.0% of Opus Genetics shares are held by institutional investors. 1.8% of Oncobiologics shares are held by insiders. Comparatively, 11.7% of Opus Genetics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Opus Genetics has higher revenue and earnings than Oncobiologics. Opus Genetics is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oncobiologics$1.35M65.03-$62.42M-$0.77N/A
Opus Genetics$14.20M27.57-$49.59M-$1.56N/A

Summary

Opus Genetics beats Oncobiologics on 10 of the 15 factors compared between the two stocks.

How does Oncobiologics compare to Rezolute?

Oncobiologics (NASDAQ:OTLK) and Rezolute (NASDAQ:RZLT) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, media sentiment, analyst recommendations, dividends, earnings, institutional ownership and profitability.

Oncobiologics has a beta of 0.75, suggesting that its share price is 25% less volatile than the broader market. Comparatively, Rezolute has a beta of 0.65, suggesting that its share price is 35% less volatile than the broader market.

In the previous week, Rezolute had 9 more articles in the media than Oncobiologics. MarketBeat recorded 10 mentions for Rezolute and 1 mentions for Oncobiologics. Oncobiologics' average media sentiment score of 0.91 beat Rezolute's score of 0.05 indicating that Oncobiologics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Oncobiologics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Rezolute
3 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Oncobiologics presently has a consensus price target of $5.20, indicating a potential upside of 1,342.04%. Rezolute has a consensus price target of $11.67, indicating a potential upside of 190.94%. Given Oncobiologics' higher probable upside, analysts clearly believe Oncobiologics is more favorable than Rezolute.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oncobiologics
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.20
Rezolute
2 Sell rating(s)
0 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.71

Oncobiologics has higher revenue and earnings than Rezolute. Rezolute is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oncobiologics$1.35M65.03-$62.42M-$0.77N/A
RezoluteN/AN/A-$77.59M-$0.76N/A

Oncobiologics' return on equity of 0.00% beat Rezolute's return on equity.

Company Net Margins Return on Equity Return on Assets
OncobiologicsN/A N/A -254.82%
Rezolute N/A -72.24%-65.90%

11.2% of Oncobiologics shares are held by institutional investors. Comparatively, 83.0% of Rezolute shares are held by institutional investors. 1.8% of Oncobiologics shares are held by company insiders. Comparatively, 15.1% of Rezolute shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Rezolute beats Oncobiologics on 7 of the 13 factors compared between the two stocks.

How does Oncobiologics compare to Sinovac Biotech?

Sinovac Biotech (NASDAQ:SVA) and Oncobiologics (NASDAQ:OTLK) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, analyst recommendations and earnings.

In the previous week, Oncobiologics had 1 more articles in the media than Sinovac Biotech. MarketBeat recorded 1 mentions for Oncobiologics and 0 mentions for Sinovac Biotech. Sinovac Biotech's average media sentiment score of 1.79 beat Oncobiologics' score of 0.91 indicating that Sinovac Biotech is being referred to more favorably in the media.

Company Overall Sentiment
Sinovac Biotech Very Positive
Oncobiologics Positive

Sinovac Biotech has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market. Comparatively, Oncobiologics has a beta of 0.75, indicating that its stock price is 25% less volatile than the broader market.

Sinovac Biotech has higher revenue and earnings than Oncobiologics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sinovac Biotech$386.01M1.67-$59.68MN/AN/A
Oncobiologics$1.35M65.03-$62.42M-$0.77N/A

Company Net Margins Return on Equity Return on Assets
Sinovac BiotechN/A N/A N/A
Oncobiologics N/A N/A -254.82%

11.2% of Oncobiologics shares are held by institutional investors. 12.8% of Sinovac Biotech shares are held by company insiders. Comparatively, 1.8% of Oncobiologics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Sinovac Biotech presently has a consensus target price of $1.00, indicating a potential downside of 84.54%. Oncobiologics has a consensus target price of $5.20, indicating a potential upside of 1,342.04%. Given Oncobiologics' higher possible upside, analysts clearly believe Oncobiologics is more favorable than Sinovac Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sinovac Biotech
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Oncobiologics
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.20

Summary

Sinovac Biotech beats Oncobiologics on 7 of the 12 factors compared between the two stocks.

Get Oncobiologics News Delivered to You Automatically

Sign up to receive the latest news and ratings for OTLK and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OTLK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OTLK vs. The Competition

MetricOncobiologicsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$96.40M$4.06B$7.83B$11.74B
Dividend YieldN/A3.63%2.47%4.47%
P/E RatioN/A26.7134.3428.32
Price / Sales65.0315.788.495.70
Price / CashN/A22.9521.0121.90
Price / Book-0.604.184.453.72
Net Income-$62.42M-$24.15M$3.52B$393.10M
7 Day Performance-25.03%-7.81%-5.93%-5.77%
1 Month Performance-26.14%-5.99%-4.58%-7.14%
1 Year Performance-81.12%-8.09%-1.94%-7.46%

Oncobiologics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OTLK
Oncobiologics
1.7407 of 5 stars
$0.36
-8.9%
$5.20
+1,342.0%
-79.6%$96.40M$1.35MN/A17
TECX
Tectonic Therapeutic
2.7087 of 5 stars
$20.38
-3.1%
$69.17
+239.4%
+9.2%$406.58MN/AN/A60
MPLT
Maplight Therapeutics
3.3302 of 5 stars
$7.11
+0.5%
$29.50
+315.2%
-52.0%$394.87MN/AN/A133
IRD
Opus Genetics
3.1784 of 5 stars
$3.99
-1.8%
$13.29
+233.4%
+132.8%$385.05M$14.20MN/A28
RZLT
Rezolute
2.8101 of 5 stars
$3.88
+0.1%
$11.22
+189.6%
-60.8%$374.83MN/AN/A58

Related Companies and Tools


This page (NASDAQ:OTLK) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners